Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition
On May 4, 2017, Atara Biotherapeutics, Inc. (the Company or
Atara) announced certain financial results for the first quarter
ended March 31, 2017.A copy of Ataras press release, titled Atara
Biotherapeutics Announces First Quarter 2017 Financial Results
and Recent Highlights is furnished as Exhibit 99.1 hereto.
In accordance with General Instruction B.2 of Form 8-K, the
information in this Current Report on Form 8-K, including Exhibit
99.1, shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act ),
or otherwise subject to the liability of that section, nor shall
it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, whether
made before or after the date hereof, except as expressly set
forth by specific reference in such filing to this Current Report
on Form 8-K.
|
Item 9.01 |
Financial Statements and Exhibits |
(d) Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
Press Release, dated May 4, 2017 |
The information in this report, including the exhibit hereto, is
being furnished and shall not be deemed filed for the purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or
otherwise subject to the liabilities of Section 11 and 12(a)(2)
of the Securities Act of 1933, as amended. The information in
this report and the attached Exhibit 99.1 shall not be
incorporated by reference into any filing with the U.S.
Securities and Exchange Commission, whether made before or after
the date hereof, except as shall be expressly set forth by
specific reference in such filing.
About Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics. Its T-cell product candidates include Epstein Barr Virus-cytotoxic T lymphocytes (EBV-CTL), which is in Phase II clinical trials for malignancies associated with EBV; cytomegalovirus (CMV)-CTL, which is in Phase II clinical trials for CMV, and Wilms Tumor 1 (WT1)-CTL, which targets cancers expressing the antigen WT1. Its molecularly targeted product candidates include STM 434, which is in Phase I clinical trial of STM 434 for ovarian cancer and other solid tumors; ATA 777, a fully human antibody targeting Activin A; ATA M43, a fully human anti-Actin-related protein 2-A (ActR2A)/2B monoclonal antibody; STM 217; ActR2B5, and ATA 842, a humanized antibody targeting myostatin. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Recent Trading Information
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) closed its last trading session up +0.20 at 15.95 with 209,311 shares trading hands.
